Other News To Note

 EnVivo Pharmaceuticals Inc., of Watertown, Mass., said the journal Neuropharmacology published data confirming the mechanism of action of its lead program EVP-6124 and demonstrating that the compound is a potent and highly selective agonist of alpha-7 neuronal nicotinic acetylcholine receptors in the brain.